Gianni Chessari,Ian R. Hardcastle,Jong Sook Ahn,Burcu Anil,Elizabeth Anscombe,Ruth H. Bawn,Luke D. Bevan,Timothy J. Blackburn,Ildiko Buck,Celine Cano,Benoit Carbain,Juan Castro,Ben Cons,Sarah J. Cully,Jane A. Endicott,Lynsey Fazal,Bernard T. Golding,Roger J. Griffin,Karen Haggerty,Suzannah J. Harnor,Keisha Hearn,Stephen Hobson,Rhian S. Holvey,Steven Howard,Claire E. Jennings,Christopher N. Johnson,John Lunec,Duncan C. Miller,David R. Newell,Martin E. M. Noble,Judith Reeks,Charlotte H. Revill,Christiane Riedinger,Jeffrey D. St. Denis,Emiliano Tamanini,Huw Thomas,Neil T. Thompson,Mladen Vinković,Stephen R. Wedge,Pamela A. Williams,Nicola E. Wilsher,Bian Zhang,Yan Zhao,Mladen Vinković

Abstract:Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02188</a>.Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_001.csv">CSV</a>)Model of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_002.cif">CIF</a>)Structure factors of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_003.cif">CIF</a>)Additional experimental details for compounds not included in the main section and analytical data for all compounds and intermediates; NMR studies on 5; X-ray structure tables; and computational chemistry (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Small Molecule Inhibitors of the P53-Mdm2

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Structure–activity Relationship and Antitumor Activity of Thio-Benzodiazepines As P53–mdm2 Protein–protein Interaction Inhibitors

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation

Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo

Computational-based drug design of novel small molecules targeting p53-MDMX interaction

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy